The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing consistent efficacy across diverse patient subgroups. Patients with lower tumor ...
Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gαq/11 are perceived as oncogenic drivers in the vast majority of uveal ...
ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...
Servier and IDEAYA Biosciences (IDYA) enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for ...
Dr Marlana M. Orloff provides an overview of the treatment landscape for metastatic uveal melanoma. Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to ...
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient's T cells ...
Credit: Shutterstock. Hepzato Kit is supplied with the Hepzato 5x5 Drug Pack and the HDS; it is expected to be available in the fourth quarter of 2023. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results